New additions to startups’ board of directors

Trevor Hawkins joins Resistell’s Board of Directors, bringing 25 years of experience from his leadership roles across research, clinical, and corporate spheres globally. He has held several senior executive roles at Siemens Healthcare, Philips, Amersham, and General Electric, while building and selling a diagnostic company based in Shanghai & San Francisco. Prior to joining HP, I was the Founder & Managing Partner at Coffee Shop Labs, a consulting and investment firm working with a portfolio of global companies such as General Electric, Northwell Health, Ping An, Google, Grifols, Ativa Medical, Datacubed and BioElectron Pharmaceuticals. His track record of innovation, coupled with a profound understanding of the healthcare industry’s challenges and opportunities, makes him an invaluable addition to the EPFL spinoff, which is focusing on developing rapid phenotypic antibiotic susceptibility testing (AST) solutions.

Two appointments at TOLREMO
TOLREMO therapeutics AG, a biotech company pioneering a unique approach to preventing non-genetic cancer drug resistance, has appointed two industry veterans Jeff Jonker and Mike Sherman to its Board of Directors to suppport its further growth as it advances its lead candidate, TT125-802, through a Phase 1 first-in-human clinical trial. Mike Sherman brings over 30 years of experience in the life sciences industry, demonstrating financial, capital-raising, and corporate management expertise. His experience spans from guiding companies through critical transitions and growth phases to navigating complex regulatory environments and executing successful M&A strategies, including his role as CEO at Endocyte, where he repositioned the company by re-prioritizing the pipeline, acquiring an external asset (PLUVICTO®), and aggressively executing a phase 3 regulatory and clinical strategy, guiding it to a $2.1 billion acquisition by Novartis in 2018. Jeff Jonker is a seasoned executive leader within biotech companies, with a career emphasizing business development and corporate strategy, complemented by deep legal and regulatory knowledge. His career is characterized by a series of high-profile roles, ranging from legal representation to executive leadership.

A new chairperson for Incephalo
Lorenz Mayr has assumed the role of Chairperson of the Board of Director at Incephalo, a pre-clinical stage startup pioneering its Compartment Lock technology for local treatment of brain cancer. With experience spanning 30 years in drug discovery, technology and innovation, business growth and financing strategy, Lorenz has served on several company boards across Europe and held several executive roles. Most recently, Lorenz was CEO of Vector BioPharma. He also has extensive global experience in pharmaceutical R&D, including positions as Vice President & Global Head at AstraZeneca and Executive Director at Novartis and Bayer Pharmaceuticals.

Klenico Health expands its board
Cornelia Wanke and Andreas Roos are the new board additions at Klenico, a digital health startup that makes mental health conditions and their symptoms visible. Its web-based system helps professionals accurately diagnose illnesses and patients understand their individual complaints to ensure the best possible treatment. The board members’ expertise and passion for improving mental health care will allow Klenico to further advance its solution to deliver a high-quality digital health solution to patients.

(RAN)